Nestlé will pay $2 billion to buy the remaining stake in Aimmune Therapeutics, gaining full ownership of the first US-approved peanut allergy treatment.
Read the full article here.
This content was originally published by Fin24 News. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Fin24 News